Clinical trial · Observational
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Pharmacogenetics of Vinorelbine in Malignant Pleural Mesothelioma Patient
NCT01865045CI-TRIAL-00060779completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on clinical outcome. Sample size: around 150 patients based on the availability of tumor size
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Mesothelioma | Pleural Malignant Mesothelioma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- no treatment
- description
- no treatment
Primary outcomes (1)
- measure
- Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR.
- timeFrame
- 2 months
Secondary outcomes (1)
- measure
- Association of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) .
- timeFrame
- 2 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * MPM patients treated with vinorelbine in the ≥ second line setting will be retrospectively analyzed * Patients will be selected based on the availability of tumor tissue Exclusion Criteria: * NA
References
Publications (0)
Data not yet available
No reference posted for this study.